5 SIMPLE STATEMENTS ABOUT ABBV-744 CLINICAL TRIAL PHASE 1 RESULTS EXPLAINED

In Section A, individuals will acquire unique doses and schedules of oral ABBV-744 tablet to determine Secure dosing program. More individuals will likely be enrolled for the determined monotherapy dosign regimen. In Section B, participants will acquire oral ruxolitinib and ABBV-744 is going to be presented as "include-on" therapy. In Phase C, cont